[go: up one dir, main page]

AU2001228742A1 - Ligand for vascular endothelial growth factor receptor - Google Patents

Ligand for vascular endothelial growth factor receptor

Info

Publication number
AU2001228742A1
AU2001228742A1 AU2001228742A AU2874201A AU2001228742A1 AU 2001228742 A1 AU2001228742 A1 AU 2001228742A1 AU 2001228742 A AU2001228742 A AU 2001228742A AU 2874201 A AU2874201 A AU 2874201A AU 2001228742 A1 AU2001228742 A1 AU 2001228742A1
Authority
AU
Australia
Prior art keywords
ligand
growth factor
vascular endothelial
factor receptor
endothelial growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228742A
Other languages
English (en)
Inventor
Valery Alakhov
Shengmin Li
Grzegorz Pietrzynski
Lioudmila Tchistiakova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supratek Pharma Inc
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of AU2001228742A1 publication Critical patent/AU2001228742A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001228742A 2000-02-04 2001-02-02 Ligand for vascular endothelial growth factor receptor Abandoned AU2001228742A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18056800P 2000-02-04 2000-02-04
US60180568 2000-02-04
PCT/IB2001/000135 WO2001057067A1 (fr) 2000-02-04 2001-02-02 Ligand du recepteur de facteur de croissance endothelial vasculaire

Publications (1)

Publication Number Publication Date
AU2001228742A1 true AU2001228742A1 (en) 2001-08-14

Family

ID=22660933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228742A Abandoned AU2001228742A1 (en) 2000-02-04 2001-02-02 Ligand for vascular endothelial growth factor receptor

Country Status (6)

Country Link
US (2) US6733755B2 (fr)
EP (1) EP1252177A1 (fr)
JP (1) JP2003528824A (fr)
AU (1) AU2001228742A1 (fr)
CA (1) CA2399022A1 (fr)
WO (1) WO2001057067A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2828100A (en) * 1999-03-04 2000-09-21 Kyowa Hakko Kogyo Co. Ltd. Diagnostics and remedies for leukemia
US6733755B2 (en) * 2000-02-04 2004-05-11 Supratek Pharma, Inc. Ligand for vascular endothelial growth factor receptor
DK1297016T3 (da) * 2000-05-12 2006-07-10 Vlaams Interuniv Inst Biotech Anvendelse af placentavækstfaktorinhibitorer til behandling af patologisk angiogenese, patologisk arteriogenese, inflammation, tumordannelse og/eller vaskulær lækage
EP1610751A4 (fr) * 2001-04-26 2006-05-24 Univ Texas Compositions therapeutiques conjuguees agent/ligand, leur methodes de synthese et leur utilisation
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (fr) 2002-03-01 2007-03-21 Dyax Corp Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
CN100475269C (zh) * 2002-03-05 2009-04-08 北京键凯科技有限公司 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途
EP1496076B1 (fr) 2002-03-13 2007-07-25 Beijing Jiankai Technology Co., Ltd. Derive polymere hydrophile a ramification de type y et procede de preparation d'un composite medical contenant le compose precite
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
ES2396368T3 (es) * 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
WO2005090570A1 (fr) * 2004-03-24 2005-09-29 Supratek Pharma Inc. Compositions therapeutiques et methodes de traitement de maladies impliquant l'angiogenese
ES2565481T3 (es) * 2005-03-24 2016-04-05 Thrombogenics N.V. Anticuerpo anti-PlGF novedoso
US20060263328A1 (en) * 2005-05-19 2006-11-23 Sang Van Hydrophilic polymers with pendant functional groups and method thereof
WO2007062105A2 (fr) * 2005-11-21 2007-05-31 The Trustees Of Columbia University In The City Of New York Immunocapture numerique multiplex utilisant une bibliotheque de marqueurs de masse photoclivable
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
US7531505B2 (en) * 2006-01-11 2009-05-12 Affinergy, Inc. Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices
BRPI0718543A2 (pt) * 2006-11-06 2013-11-12 Novartis Ag Dispositivos oculares e métodos de fabricação e uso dos mesmos
WO2010005527A1 (fr) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Traitement de maladies oculaires et d’une néovascularisation excessive utilisant un traitement combiné
US20110150837A1 (en) * 2009-12-23 2011-06-23 Flamel Technologies Amphiphilic polymer functionalized by methionine
WO2011119995A2 (fr) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations et procédés d'utilisation
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
CA3012718A1 (fr) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions a demi-vie intravitreenne amelioree et leurs utilisations
WO2017200173A1 (fr) * 2016-05-19 2017-11-23 삼성전자 주식회사 Mutant de fragment de liaison au vegf, et protéine de fusion comprenant le mutant de fragment de liaison au vegf et anticorps anti-c-met
US11702462B2 (en) 2017-07-19 2023-07-18 Rutgers, The State University Of New Jersey Gene transfer systems for stem cell engineering

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870160A (en) * 1987-08-19 1989-09-26 Regents Of The University Of Minnesota Polypeptides with laminin activity
US6762290B1 (en) * 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
DE69736222T2 (de) * 1996-11-21 2007-05-24 Kyowa Hakko Kogyo K.K. Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
DE69940733D1 (de) * 1998-05-20 2009-05-28 Kyowa Hakko Kogyo Kk Gen rekombinante antikörper
WO2000055206A1 (fr) * 1999-03-18 2000-09-21 The Hope Heart Institute Stimulation de cellules endotheliales a l'aide d'un complexe de fibronectine et de facteur de croissance endotheliale vasculaire
US6733755B2 (en) * 2000-02-04 2004-05-11 Supratek Pharma, Inc. Ligand for vascular endothelial growth factor receptor

Also Published As

Publication number Publication date
EP1252177A1 (fr) 2002-10-30
US20020058619A1 (en) 2002-05-16
CA2399022A1 (fr) 2001-08-09
JP2003528824A (ja) 2003-09-30
US20040266694A1 (en) 2004-12-30
WO2001057067A1 (fr) 2001-08-09
US7112654B2 (en) 2006-09-26
US6733755B2 (en) 2004-05-11

Similar Documents

Publication Publication Date Title
AU2001228742A1 (en) Ligand for vascular endothelial growth factor receptor
AU2002252631A1 (en) Vascular endothelial growth factor 2
AU5023300A (en) Vascular endothelial growth factor variants
AU2001246835A1 (en) Ethylenediamine derivatives
AU1486401A (en) Shelving bracket
AU2002256172A1 (en) Vascular endothelial growth factor 2
AU1897700A (en) Removable stent
AU1290001A (en) Antibodies
AU2001281758A1 (en) Biocompatible materials
EP1313512A4 (fr) Facteur 2 de croissance endoth liale (vegf-2)
AUPR030900A0 (en) Growth factor complex
AUPQ910500A0 (en) Support means
AU4935000A (en) Antibodies
AU2001236179A1 (en) Supporting arm for surgical purposes
AU2001284048A1 (en) Support beam
AU6202500A (en) Durable multilayer nonwoven materials
AU2722400A (en) Real-time planner for design
AU5319700A (en) Nicotine receptor ligands
AU2001259195A1 (en) Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
AU5026100A (en) Vascular endothelial growth factor dimers
AU2002212374A1 (en) Automatic dispenser
AU2001288392A1 (en) Delivery system for heparin-binding growth factors
AU2001240557A1 (en) Implant for cranioplastics
AU2002313770A1 (en) Vascular endothelial growth factor 2
AU4781100A (en) Ip3 receptor ligands